首页> 外文期刊>Oncology letters >Non-small cell neuroendocrine carcinoma of the ovary in a BRCA2-germline mutation carrier: A case report and brief review of the literature
【24h】

Non-small cell neuroendocrine carcinoma of the ovary in a BRCA2-germline mutation carrier: A case report and brief review of the literature

机译:在BRCA2-GRENLINE突变载体中卵巢的非小细胞神经内分泌癌:提出报告和对文献的简要审查

获取原文
获取原文并翻译 | 示例
           

摘要

Non-small cell neuroendocrine carcinomas (NSCNEC) account for 2% of gynecological cancer cases and are associated with a poor prognosis due to delayed diagnosis and aggressive tumor behavior. BRCA2-associated ovarian carcinomas predominantly possess a high-grade serous phenotype, which respond to platinum and targeted therapy with PARP inhibitors. Presented here is the case of an adult patient with NSCNEC of the ovaries associated with a deleterious BRCA2 germline mutation. The pathogenic mutation was also confirmed on the somatic level, while the wild-type allele had a high variant fraction, suggesting loss of heterozygosity. To the best of our knowledge, this is the first report of an adult BRCA2 germline mutation carrier with the rare NSCNEC of the ovary phenotype. Therefore, ovarian cancer patients with histological subtypes other than high-grade serous carcinomas should be tested for BRCA1/2 mutations, as they may benefit from targeted therapy with poly (ADP-ribose) polymerase inhibitors.
机译:非小细胞神经内分泌癌(NSCNEC)占妇科癌症病例的2%,并且由于延迟诊断和侵袭性肿瘤行为而导致预后差。 BRCA2相关的卵巢癌主要具有高级浆液表型,可与PARP抑制剂进行铂和靶向治疗。这里介绍了与卵巢的成人患者有关的卵巢,与有害的BRCA2种系突变相关。在体细胞水平上也证实了致病性突变,而野生型等位基因具有高变种级分,则表明杂合性丧失。据我们所知,这是成人BRCA2种系突变载体的第一个报告,其中卵巢表型罕见的NSCNEC。因此,应对BRCA1 / 2突变进行高级浆液癌以外的组织学亚型的卵巢癌患者,因为它们可以从具有聚(ADP-核糖)聚合酶抑制剂的靶向治疗中受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号